


Future of Vaccines Market to hit \$108.82B by 2032 | Market Analysis, Trends, COVID-19 Impact

Vaccines Market Size 2025–2033: Growth Outlook, Trends, COVID-19 Impact & Forecast Analysis

AUSTIN, TX, UNITED STATES, November 19, 2025 /EINPresswire.com/ -- Market Size and Growth

According to DataM Intelligence, theGlobal [Vaccines Market](#) was valued at US\$ 77.01 billion in 2024 and is projected to grow to US\$ 108.82 billion by 2032, registering a CAGR of 3.9% forecast period. 2025–2032.



Vaccines Market

Rising disease outbreaks, strong government immunization programs, and rapid adoption of mRNA and recombinant vaccine technologies are accelerating global demand. The shift toward next-generation platforms such as DNA vaccines, vector-based vaccines, and intranasal formulations is reshaping the global public health landscape.



Vaccines Market Forecast
2025–2032: Global Revenue
to Hit \$108.82B | USA Leads
in Vaccine Adoption, R&D
Investments, and
Immunization Coverage”
*DataM Intelligence 4Market
Research LLP*

Vaccines remain a cornerstone of preventive healthcare, reducing mortality, enabling pandemic preparedness, and lowering chronic disease burden worldwide.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):–

[https://www.datamintelligence.com/download-](https://www.datamintelligence.com/download-sample/vaccines-market)

[sample/vaccines-market](#)

Browse in-depth TOC on "Vaccines Market"

50 – Tables
45 – Figures
180 – Pages

Growth Drivers

1. Over 1.4 billion vaccine doses were administered globally in 2024; demand projected to cross 2.2 billion doses by 2032.
2. mRNA vaccine R&D investment exceeded USD 15 billion in 2024.
3. WHO and GAVI expanded immunization coverage across 67 low-income nations, boosting vaccine uptake.
4. Increasing emergence of [infectious diseases](#), including [RSV](#), influenza variants, and zoonotic viruses.
5. Rising adoption of combination and pediatric vaccines to streamline national immunization schedules.

□ Pfizer–BioNTech COVID-19 Vaccine Update

In September 2023, Pfizer and BioNTech received FDA approval for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 12+, along with emergency use authorization for children 6 months to 11 years, expanding protection across all age groups.

□ Global Measles Surge – WHO & CDC Update

According to WHO and CDC (2024), global measles cases climbed to 10.3 million in 2023, marking a 20% jump from 2022, largely driven by immunization gaps that emerged during the pandemic.

□ Merck CAPVAXIVE Approval

In June 2024, Merck secured FDA approval for CAPVAXIVE, the 21-valent pneumococcal conjugate vaccine, offering broader protection against invasive pneumococcal disease and pneumonia in adults 18+.

□ Pfizer PREVNAR 20 Pediatric Approval

In April 2023, Pfizer gained FDA approval for PREVNAR 20 for infants to 17-year-olds, enabling protection against 20 pneumococcal serotypes responsible for invasive pneumococcal disease.

□ FDA Approval for Priorix (MMR Vaccine)

The FDA approved Priorix for immunizing individuals 12 months and older against measles, mumps, and rubella a globally trusted vaccine with 800M+ doses distributed across 100+

countries.

▣ Mylab & Serum Institute Launch Nasovac S4

Mylab and Serum Institute of India introduced Nasovac S4, the country's first needle-free nasal influenza vaccine, delivering protection against four flu strains and improving vaccine comfort and uptake.

Market Segmentation Analysis

By Technology

mRNA Vaccines accounted for 28% (USD 13.2 billion), projected to reach USD 40 billion by 2032.

Recombinant/Subunit Vaccines hold 32% share (USD 15 billion).

Live Attenuated & Inactivated Vaccines represent 30%, still widely used in low-cost mass immunization.

By Disease Indication

Influenza: 20% market share

HPV: 15% share

COVID-19: 12% share

Pneumococcal & Meningococcal: 18% share

Others (RSV, TB, Rotavirus, Hepatitis): 35%

Request for Customized Sample Report as per Your Business Requirement:

<https://www.datamintelligence.com/customize/vaccines-market>

Industry Developments

▣ Cambodia MR Immunization Drive

In October 2024, Cambodia launched a nationwide measles–rubella (MR) immunization campaign to protect 1.5 million children under five across 25 provinces, supported by Gavi, WHO, UNICEF, and CHAI.

▣ Zambia Measles Vaccination Campaign

In September 2024, Zambia rolled out a major measles vaccination drive targeting four million children aged 9 months to 5 years, addressing coverage gaps caused by the COVID-19 pandemic.

□ UK NHS MMR Catch-Up Campaign

In January 2024, the NHS launched a nationwide MMR catch-up campaign, urging parents across England to vaccinate their children amid rising measles cases.

□ Moderna Combined Flu + COVID-19 Vaccine Success

In June 2024, Moderna announced that its Phase 3 trial for mRNA-1083, a dual influenza and COVID-19 vaccine, met its primary goals showing stronger immune responses than existing comparator vaccines.

Regional Insights

United States

1. The U.S. vaccines market was USD 14.6 billion in 2024, expected to reach USD 38.5 billion by 2032.
2. Strong CDC and federal vaccination programs.
3. Rapid uptake of mRNA boosters and RSV vaccines.
4. High R&D investments by Pfizer, Moderna, and J&J.

Japan

1. Japan's vaccines market was USD 3.1 billion in 2024, growing to USD 7.9 billion by 2032.
2. Rising elderly population drives demand for flu, pneumonia, and shingles vaccines.
3. The government pushes for domestic mRNA production.

Key Players

EMERGENT || Johnson & Johnson Services, Inc. || Bavarian Nordic || Pfizer || Moderna || GSK || Sanofi || Merck & Co || AstraZeneca || Bharat Biotech || Serum Institute of India

Key Highlights

1. Moderna generated over USD 9 billion in global mRNA revenues.
2. Pfizer invested USD 3.2 billion in multivalent flu and RSV pipeline expansion.
3. GSK's Shingrix surpassed USD 4 billion revenue in 2024.

Recent Developments

1. Moderna launched next-gen pan-respiratory mRNA vaccine (2025).
2. Pfizer initiated Phase III trials for universal influenza vaccine (Feb 2025).
3. GSK expanded its meningococcal vaccine manufacturing unit (Jan 2025).

Market Outlook

mRNA & DNA vaccines to reach 40% market share by 2032.

Vaccine self-administration devices emerging as a USD 5B opportunity.

Global immunization programs to expand coverage by 60 million children by 2030.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): <https://www.datamintelligence.com/buy-now-page?report=vaccines-market>

Conclusion

According to DataM Intelligence, the Vaccines Market is entering a transformational era led by platform innovation, rapid regulatory approvals, and growing health security requirements. The industry will surpass USD 108.82 billion by 2032, positioning vaccines as one of the fastest-growing segments in global healthcare.

Related Reports:

Avian Influenza Treatment Market Rising to \$28.2B by 2033 - DataM Intelligence @ <https://www.datamintelligence.com/research-report/avian-influenza-treatment-market>

Pediatric Vaccines Market Growing to \$38.5B by 2033 - DataM Intelligence @ <https://www.datamintelligence.com/research-report/pediatric-vaccines-market>

Viral Vector Vaccines Market Set for CAGR of 14% By 2031 - DataM Intelligence @ <https://www.datamintelligence.com/research-report/viral-vector-vaccines-market>

Vaccine Delivery Devices Market outlook CAGR of 7.2% by 2031 - DataM Intelligence @ <https://www.datamintelligence.com/research-report/vaccine-delivery-devices-market>

Sai Kiran

DataM Intelligence 4market Research LLP

+1 877-441-4866

sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/868469649>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.